



OIPE

RAW SEQUENCE LISTING  
 PATENT APPLICATION: US/09/730,174

DATE: 01/26/2002  
 TIME: 13:53:51

Input Set : N:\EBONY'S\ES.txt  
 Output Set: N:\CRF3\01262002\I730174.raw

Does Not Comply  
 (Corrected Diskette Name)

3 <110> APPLICANT: R.J. ZAHRADNIK  
 W--> 4 <120> TITLE OF INVENTION: ANTIBODIES AND PEPTIDE ANTIGENS FOR PRODUCING ANTIBODIES  
 HAVING A  
 W--> 5 SELECTIVE BINDING SPECIFICITY TO BIOACTIVE INTACT PARATHYROID HORMONE (PTH) 1 84  
 W--> 6 <130> FILE REFERENCE: IMUNE-001A  
 W--> 7 <140> CURRENT APPLICATION NUMBER: 09/730,174  
 C--> 8 <141> CURRENT FILING DATE: 2002-01-09  
 E--> 8 <160> NUMBER OF SEQ ID: 12

*See  
 following pages*

## ERRORED SEQUENCES

10 <210> SEQ ID NO: 1  
 11 <211> LENGTH: 11  
 12 <212> TYPE: PRT  
 13 <213> ORGANISM: ARTIFICIAL SEQUENCE  
 W--> 14 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES  
 W--> 14 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES  
 15 <223> OTHER INFORMATION:  
 W--> 16 <400> SEQUENCE: 001; VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY  
 E--> 16 001; VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY  
 18 <210> SEQ ID NO: 2  
 19 <211> LENGTH: 11  
 20 <212> TYPE: PRT  
 21 <213> ORGANISM: ARTIFICIAL SEQUENCE  
 W--> 22 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES  
 W--> 22 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES  
 23 <223> OTHER INFORMATION:  
 W--> 24 <400> SEQUENCE: 002; VAL SER GLU ILE GLN PHE MET HIS ASN LEU GLY  
 E--> 24 002; VAL SER GLU ILE GLN PHE MET HIS ASN LEU GLY  
 26 <210> SEQ ID NO: 3  
 27 <211> LENGTH: 12  
 28 <212> TYPE: PRT  
 29 <213> ORGANISM: ARTIFICIAL SEQUENCE  
 W--> 30 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES  
 W--> 30 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES  
 31 <223> OTHER INFORMATION:  
 W--> 32 <400> SEQUENCE: 003; SER VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY  
 E--> 32 003; SER VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY  
 34 <210> SEQ ID NO: 4  
 35 <211> LENGTH: 12  
 36 <212> TYPE: PRT  
 37 <213> ORGANISM: ARTIFICIAL SEQUENCE  
 W--> 38 <220> FEATURE: INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES

09/730,174

2

## SEQUENCE LISTING

<110> R.J. ZAHRADNIK  
 <120> ANTIBODIES AND PEPTIDE ANTIGENS FOR PRODUCING ANTIBODIES HAVING A  
 SELECTIVE BINDING SPECIFICITY TO BIOACTIVE INTACT PARATHYROID HORMONE (PTH) 1 84  
 <130> IMUNE-001A  
 <140> 09/730,174 → <141> ← insert this name identifier and response  
 <160> 12

<210> 1  
 <211> 11  
 <212> PRT  
 <213> ARTIFICIAL SEQUENCE  
 <220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES' more explanation  
 <223> ← 1 insert hard return more amino acids to line below to <223> line  
 <400> 001: VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY 24007  
                     1                    5                    10

<210> 2  
 <211> 11  
 <212> PRT  
 <213> ARTIFICIAL SEQUENCE  
 <220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES.  
 <223> ← 1 hard return  
 <400> 002: VAL SER GLU ILE GLN PHE MET HIS ASN LEU GLY  
                     1                    5                    10

<210> 3  
 <211> 12  
 <212> PRT  
 <213> ARTIFICIAL SEQUENCE  
 <220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES  
 <223> ← 1 hard return  
 <400> 003: SER VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY  
                     1                    5                    10

<210> 4  
 <211> 12  
 <212> PRT  
 <213> ARTIFICIAL SEQUENCE  
 <220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES.  
 <223> ← 1 hard return  
 <400> 40: SER VAL SER GLU ILE GLN PHE MET HIS ASN LEU GLY  
                     1                    5                    10

<210> 5  
 <211> 12  
 <212> PRT  
 <213> ARTIFICIAL SEQUENCE  
 <220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES  
 <223> ← 1 hard return  
 <400> 50: ALA VAL SER GLU ILE GLN LEU MET HIS ASN LEU GLY  
                     1                    5                    10

<210> 6  
 <211> 12  
 <212> PRT  
 <213> ARTIFICIAL SEQUENCE  
 <220> INDUCES FORMATION OF ANTIBODIES AND ISOLATES SAID ANTIBODIES  
 <223> ← 1 hard return  
 <400> 60: ALA VAL SER GLU ILE GLN PHE MET HIS ASN LEU GLY  
                     1                    5                    10

(sample of global errors)  
 Please consult sample sequence listing (attached) for valid format

Do NOT insert any response to <220>.  
 <220> is a "header" only.  
 Use upper-case letter for the initial letter of amino acid  
 e.g. Val  
       Ser  
       Glu  
       Ile  
       Gln  
       =

not VAL  
       SER  
       GLU

<110> Smith, John; Smithgene Inc.

<120> Example of a Sequence Listing

<130> 01-00001

<140> PCT/EP98/00001  
<141> 1998-12-31

<150> US 08/999,999  
<151> 1997-10-15

<160> 4

<170> PatentIn version 2.0

<210> 1  
<211> 389  
<212> DNA  
<213> Paramecium sp.

<220>  
<221> CDS  
<222> (279)...(389)

<300>  
<301> Doe, Richard  
<302> Isolation and Characterization of a Gene Encoding a  
Protease from Paramecium sp.  
<303> Journal of Genes  
<304> 1  
<305> 4  
<306> 1-7  
<307> 1988-06-31  
<308> 123456  
<309> 1988-06-31

<400> 1  
agctgtagtc attcctgtgt cctcttctct ctgggtctct caccctgcta atcagatctc 60  
agggagagtg tcttgacct cctctgctt tgcagcttca caggcaggca ggcaggcagc 120  
tgaatgtggca attcctggca gtggacagg cctctcagca aggttgggg tggatccgc 180  
cgcggcgagg cggccctct cgcgtctct tcgcgctct ctctcgctct cctctcgctc 240

Please consult

Appendix 3, page 2

ggacctgatt aggtgagcag gaggagggggg cagtttagc atg gtt tca atg ttc agc 296  
Met Val Ser Met Phe Ser

ttg tct ttc aaa tgg cct gga ttt tgt ttg ttt gtt tgt ttg ttc caa 344  
Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val Cys Leu Phe Gln

tgt ccc aaa gtc ctc ccc tgt cac tca tca ctg cag ccg aat ctt 389  
Cys Pro Lys Val Leu Pro Cys His Ser Ser Leu Gln Pro Asn Leu

<210> 2  
<211> 37  
<212> PRT  
<213> Paramecium sp.

<400> 2  
Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu  
1 5 10 15

Phe Val Cys Leu Phe Gln Cys Pro Lys Val Leu Pro Cys His Ser Ser  
20 25 30

Leu Gln Pro Asn Leu  
35

<210> 3  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3  
Met Val Asn Leu Glu Pro Met His Thr Glu Ile  
1 5 10

<210> 4  
<400> 4  
000

[Annex VIII follows]

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO: #	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

in feature

use was used in  
a sequence

<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<300>	Publication Information	Leave blank after <300>	0
<301>	Authors	Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials	0
<302>	Title		0
<303>	Journal		0
<304>	Volume		0
<305>	Issue		0
<306>	Pages		0
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MM-yyyy or Season-yyyy	0
<308>	Database Accession Number	Accession number assigned by database including database name	0
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MM-yyyy	0
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	0

<311>

Patent Filing  
Date

Document filing  
date, for patent-  
type citations only;  
specify as yyyy-mm-dd

<312>

Publication Date

Document publication  
date, for  
patent-type  
citations only;  
specify as yyyy-mm-dd

<313>

Relevant  
Residues

FROM (position) TO  
(position)

<400>

Sequence

SEQ ID NO should  
follow the  
numeric identifier  
and should appear  
on the line pre-  
ceding the actual  
sequence

5. Section 1.024 is revised to read as follows:

1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.021(c) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.


(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;





0590  
022

## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/730,174  
Source: OPE  
Date Processed by STIC: 1/26/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/efb/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002